Linker Information
General Information of This Linker
| Linker ID |
LIN0XFAOS
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
IgG (8)-m- (b-PEG12)-VC-MMAE
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C66H113N9O22
|
|||||
| Isosmiles |
O=C(C=C1)N(CCCCCC(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C(NCCCCCC(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC2=CC=C(CO)C=C2)=O)=O)=O)=O)=O)C1=O
|
|||||
| InChI |
InChI=1S/C66H113N9O22/c1-52(2)62(65(84)73-56(14-12-26-70-66(67)85)64(83)71-54-19-17-53(51-76)18-20-54)74-59(79)16-6-4-9-25-69-63(82)55(72-58(78)15-7-5-11-27-75-60(80)21-22-61(75)81)13-8-10-24-68-57(77)23-28-87-31-32-89-35-36-91-39-40-93-43-44-95-47-48-97-50-49-96-46-45-94-42-41-92-38-37-90-34-33-88-30-29-86-3/h17-22,52,55-56,62,76H,4-16,23-51H2,1-3H3,(H,68,77)(H,69,82)(H,71,83)(H,72,78)(H,73,84)(H,74,79)(H3,67,70,85)/t55-,56-,62-/m0/s1
|
|||||
| InChIKey |
QIZGBLFWUQFWCT-VNJAPNFOSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1384.671
|
Polar area
|
398.09
|
||
|
Complexity
|
2192.772904
|
xlogp Value
|
1.3439
|
|||
|
Heavy Count
|
97
|
Rot Bonds
|
66
|
|||
|
Hbond acc
|
22
|
Hbond Donor
|
9
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
mb (4)-m- (b-PEG12)-VC-MMAE [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.022 nM
|
High HER2 expression (HER2+++) | ||
| Method Description |
IC50 (in nM) cell-based assays of tested entities on breast cancer cell lines MDA-MB-231 (HER2-low)
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (HER2 low) | CVCL_0062 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
312.1 nM
|
Low HER2 expression (HER2+) | ||
| Method Description |
IC50 (in nM) cell-based assays of tested entities on breast cancer cell lines MDA-MB-231 (HER2-low)
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (HER2 low) | CVCL_0062 | ||
igG (8)-m- (b-PEG12)-VC-MMAE [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.029 nM
|
High HER2 expression (HER2+++) | ||
| Method Description |
IC50 (in nM) cell-based assays of tested entities on breast cancer cell lines MDA-MB-231 (HER2-low)
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (HER2 low) | CVCL_0062 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 100 nM | Low HER2 expression (HER2+) | ||
| Method Description |
IC50 (in nM) cell-based assays of tested entities on breast cancer cell lines MDA-MB-231 (HER2-low)
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (HER2 low) | CVCL_0062 | ||
References